Pathstone Family Office’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $323K | Buy |
+2,870
| New | +$323K | ﹤0.01% | 1263 |
|
|
2023
Q1 | – | Sell |
-2,091
| Closed | -$250K | – | 1387 |
|
|
2022
Q4 | $250K | Buy |
2,091
+33
| +2% | +$3.94K | ﹤0.01% | 1303 |
|
|
2022
Q3 | $219K | Buy |
+2,058
| New | +$219K | ﹤0.01% | 1303 |
|
|
2017
Q4 | – | Sell |
-250
| Closed | -$15K | – | 189 |
|
|
2017
Q3 | $15K | Buy |
+250
| New | +$15K | 0.01% | 114 |
|